BV-101 / Bayer - LARVOL DELTA

A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease (clinicaltrials.gov) - P1/2 | N=5 | Active, not recruiting | Sponsor: Brainvectis, a subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio) | Trial completion date: Dec 2029 ➔ Apr 2028

Trial completion date • Gene Therapies • Genetic Disorders • Huntington's Disease • Movement Disorders

A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease (clinicaltrials.gov) - P1/2 | N=5 | Active, not recruiting | Sponsor: Brainvectis, a subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio) | Recruiting ➔ Active, not recruiting | N=18 ➔ 5

Enrollment change • Enrollment closed • Gene Therapies • Genetic Disorders • Huntington's Disease • Movement Disorders • NEFL

A Study to Evaluate BV-101 Striatal Administration in Adults With Early Manifest Huntington's Disease (clinicaltrials.gov) - P1/2 | N=18 | Recruiting | Sponsor: Brainvectis, a subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio) | Not yet recruiting ➔ Recruiting

Enrollment open • Gene Therapies • Genetic Disorders • Huntington's Disease • Movement Disorders • NEFL

Gene therapy for Huntington disease : from metabolic disease to A Phase I/II Dose-Finding study to Evaluate BV-101 Striatal Administration in Adults with Early Manifest Hutington’s disease (ESGCT 2022) - No abstract available

Clinical • P1/2 data • Gene Therapies • Huntington's Disease • Metabolic Disorders • Movement Disorders

PhI/II Dose-Finding Study to Evaluate BV-101 Striatal Administration in Adults With Early Manifest Huntington's Disease (clinicaltrials.gov) - P1/2 | N=18 | Not yet recruiting | Sponsor: Brainvectis, a subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio)

New P1/2 trial • Gene Therapies • Genetic Disorders • Huntington's Disease • Movement Disorders • NEFL

BrainVectis, a subsidiary of AskBio, receives clearance to conduct Phase I/II clinical trial in France for its novel gene therapy for early-stage Huntington’s Disease (PRNewswire) - “Asklepios BioPharmaceutical, Inc…has received clearance to conduct a Phase I/II trial for its novel Huntington's Disease (HD) gene therapy, BV-101, in France through its subsidiary BrainVectis. This authorization, provided by the National Agency for Safety of Medicines and Health Products (ANSM), the country's governing drug authority, along with the approval of the trial protocol by the Ethics Committee in charge, enables the company to begin recruiting participants….The trial will include 12-18 participants and is expected to begin in Paris in Q4, 2022.”

New P1/2 trial • Trial initiation date • CNS Disorders • Huntington's Disease

AskBio Acquires BrainVectis to Expand its Clinical Pipeline for Neurodegenerative Diseases (GlobeNewswire, Asklepios BioPharmaceutical, Inc.) - “Asklepios BioPharmaceutical…announced that it has acquired BrainVectis, a Paris-based gene therapy company and French National Institute for Health and Medical Research (INSERM) spin-out with expertise and an intellectual property estate for the treatment of neurodegenerative disorders. BrainVectis is particularly focused on therapies that restore brain cholesterol metabolism as a treatment for Huntington's disease and other disorders.”

M&A • Alzheimer's Disease • CNS Disorders • Genetic Disorders • Huntington's Disease • Tauopathies And Synucleinopathies